Verteporfin

TargetMol
Product Code: TAR-T3112
Supplier: TargetMol
CodeSizePrice
TAR-T3112-2mg2mg£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3112-5mg5mg£134.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3112-10mg10mg£166.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3112-1mL1 mL * 10 mM (in DMSO)£172.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3112-25mg25mg£261.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3112-50mg50mg£432.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3112-100mg100mg£461.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Verteporfin, a benzoporphyrin derivative monoacid ring A, can inhibit the activity of YAP.
CAS:
129497-78-5
Formula:
C82H84N8O16
Molecular Weight:
1437.614
Pathway:
Apoptosis; Angiogenesis; Autophagy; Stem Cells
Purity:
0.9982
SMILES:
COC(=O)CCc1c(C)c2cc3[nH]c(cc4nc(cc5[nH]c(cc1n2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC.COC(=O)CCc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)[C@]1(C)[C@H](C(=O)OC)C(=CC=C41)C(=O)OC)c(C)c3C=C
Target:
Apoptosis; YAP; VDA; Autophagy

References

1. Schmidt-Erfurth U, et al. Surv Ophthalmol, 2000, 45(3), 195-214. 2. Granville DJ, et al. Blood, 2000, 95(1), 256-262. 3. Liu-Chittenden Y, et al. Genes Dev. 2012, 26(12):1300-5. 4. Isfort I, Elges S, Cyra M, et al. Prevalence of the Hippo Effectors YAP1/TAZ in Tumors of Soft Tissue and Bone[J]. Scientific Reports. 2019, 9(1): 1-9. 5. Zhuang Q, Li F, Liu J, et al. Nuclear exclusion of YAP exacerbates podocyte apoptosis and disease progression in Adriamycin-induced focal segmental glomerulosclerosis[J]. Laboratory Investigation. 2021, 101(2): 258-270. 6. Ilka Isfort, Magdalene Cyra, Sandra Elges, Sareetha Kailayangiri, Bianca Altvater, Claudia Rossig, Konrad Steinestel et al. SS18-SSX-dependent YAP/TAZ Signaling in Synovial Sarcoma [J]. Clinical Cancer Research. 2019 Feb 27: clincanres-3553. 7. Marcel Trautmann, Ya-Yun Cheng, Patrizia Jensen, Ninel Azoitei, Ines Brunner, Jennifer H?llein, Mikolaj Slabicki et al. Requirement for YAP1 signaling in myxoid liposarcoma [J]. EMBO molecular medicine. 2019 May;11(5): e9889. 8. Tang Y, Fang G, Guo F, et al. Selective Inhibition of STRN3-Containing PP2A Phosphatase Restores Hippo Tumor-Suppressor Activity in Gastric Cancer[J]. Cancer Cell. 2020, 38(1): 115-128. e9. 9. Peng G, Suo S, Cui G, et al. Molecular architecture of lineage allocation and tissue organization in early mouse embryo[J]. Nature. 2019, 572(7770): 528-532.